Cytokinetics, Incorporated

Historical 13F Holders

Symbol
CYTK
CUSIP
23282W605
All holders as of
Q2 2026
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 23282W605 since 12/18/2024, newest first.

Filer % of Class Filed
Wellington Management Group LLP 13G/A Amendment 2
5.1% 8/13/2026
Event 6/30/2026
FMR LLC 13G/A Amendment 8
3.9% 7/8/2026
Event 6/30/2026
FMR LLC 13G/A Amendment 7
9.0% 5/6/2026
Event 3/31/2026
Vanguard Capital Management LLC 13G 5.2% 4/29/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 11 0% 3/26/2026
Event 3/13/2026
T. Rowe Price Investment Management, Inc. 13G/A Amendment 3 14.5% 2/17/2026
Event 12/31/2025
T. Rowe Price Investment Management, Inc. 13G/A Amendment 2 16.0% 11/14/2025
Event 9/30/2025
State Street Corp 13G 4.7% 11/10/2025
Event 9/30/2025
T. Rowe Price Investment Management, Inc. 13G/A Amendment 1 14.7% 8/14/2025
Event 6/30/2025
FMR LLC 13G/A Amendment 6
10.9% 8/7/2025
Event 7/31/2025
T. Rowe Price Investment Management, Inc. 13G 11.3% 5/7/2025
Event 4/30/2025
FMR LLC 13G/A Amendment 5
9.4% 2/12/2025
Event 12/31/2024
Vanguard Group Inc 13G/A Amendment 10 10.1% 1/8/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 22 303 k $19.9 M
2026 Q2 517 171 M $13.8 B
2026 Q1 497 146 M $9.64 B
2025 Q4 484 149 M $9.46 B
2025 Q3 431 143 M $7.83 B
2025 Q2 356 138 M $4.55 B
2025 Q1 394 137 M $5.58 B
2024 Q4 386 132 M $6.18 B
2024 Q3 408 138 M $7.28 B
2024 Q2 404 138 M $7.46 B
2024 Q1 469 121 M $8.45 B
2023 Q4 444 120 M $9.99 B
2023 Q3 290 110 M $3.24 B
2023 Q2 275 110 M $3.60 B
2023 Q1 281 111 M $3.92 B
2022 Q4 304 114 M $5.25 B
2022 Q3 302 105 M $5.09 B
2022 Q2 284 106 M $4.16 B
2022 Q1 258 95.6 M $3.52 B
2021 Q4 271 91.6 M $4.17 B
2021 Q3 229 90.3 M $3.22 B
2021 Q2 203 75.6 M $1.50 B
2021 Q1 206 74.8 M $1.74 B
2020 Q4 201 73.0 M $1.52 B
2020 Q3 210 68.9 M $1.49 B
2020 Q2 170 57.9 M $1.36 B
2020 Q1 159 55.7 M $658 M
2019 Q4 149 55.8 M $592 M
2019 Q3 155 44.5 M $506 M
2019 Q2 148 44.0 M $495 M
2019 Q1 145 39.2 M $317 M
2018 Q4 143 40.3 M $255 M
2018 Q3 130 39.1 M $385 M
2018 Q2 134 37.7 M $313 M
2018 Q1 133 37.1 M $267 M
2017 Q4 139 38.4 M $313 M
2017 Q3 144 39.5 M $573 M
2017 Q2 141 38.2 M $463 M
2017 Q1 114 28.6 M $368 M
2016 Q4 106 26.7 M $324 M
2016 Q3 98 26.7 M $245 M
2016 Q2 98 26.5 M $252 M
2016 Q1 112 26.6 M $188 M
2015 Q4 132 26.5 M $277 M
2015 Q3 109 21.6 M $145 M
2015 Q2 104 20.8 M $139 M
2015 Q1 97 19.6 M $133 M
2014 Q4 89 19.3 M $155 M
2014 Q3 92 19.8 M $69.7 M
2014 Q2 100 21.2 M $101 M
2014 Q1 129 22.8 M $216 M